Final Survival Results From Spartan, A Phase Iii Study Of Apalutamide (Apa) Versus Placebo (Pbo) In Patients (Pts) With Nonmetastatic Castration-Resistant Prostate Cancer (Nmcrpc).

Eric Jay Small,Fred Saad,Simon Chowdhury,Stephane Oudard,Boris A. Hadaschik,Julie N Graff,David Olmos,Paul N. Mainwaring,Ji Youl Lee,Hiroji Uemura,Peter De Porre,Andressa Smith,Sabine Doris Brookman-May,Susan Li,Ke Zhang,Oliver Brendan Rooney,Angela Lopez-Gitlitz,Matthew Raymond Smith

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 70|浏览47

暂无评分

摘要

5516Background: SPARTAN evaluated APA vs PBO in pts with nmCRPC and a prostate-specific antigen doubling time of ≤ 10 mo receiving androgen deprivation therapy (ADT). At primary end point analysis ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要